Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of IgD-Fc-Ig fusion protein in preparation of drugs for treating acute lymphocytic leukemia

An acute lymphocyte, igd-fc-ig technology, applied in the field of IgD-Fc-Ig fusion protein, can solve the problems of unclear IgD/IgDR-related functions and few researches on IgD/IgDR-related signaling pathways, and achieve stability. Good sex, improve half-life effect

Pending Publication Date: 2018-11-06
魏伟
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both in vitro cell experiments and animal experiments have found that the combination of IgD and IgDR on T cells can lead to an abnormal increase in the expression of IgDR, but the related functions of IgD / IgDR are still unclear, and there are few studies on IgD / IgDR related signaling pathways

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of IgD-Fc-Ig fusion protein in preparation of drugs for treating acute lymphocytic leukemia
  • Application of IgD-Fc-Ig fusion protein in preparation of drugs for treating acute lymphocytic leukemia
  • Application of IgD-Fc-Ig fusion protein in preparation of drugs for treating acute lymphocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: IgD, IgD-Fc-Ig fusion protein competition binding experiment

[0024] 1.1 Experimental method

[0025] CD4+ T cells, Jurkat and MOLT-4 cells were all treated with 2×10 6 The cell density per well was spread in 6-well plate, and FITC-IgD (10 μg / ml) and different concentrations of IgD-Fc-Ig fusion protein (0.03, 0.1, 0.3, 1, 3, 10, 30 μg / ml) were added respectively, 37 Incubate at ℃ for 2h. Wash twice with PBS, 300g×10min, discard the supernatant, resuspend the cells with an appropriate amount of PBS, and detect the fluorescence intensity on the machine. The binding properties of ligand IgD, IgD-Fc-Ig fusion protein and IgDR were calculated by Fluorescent Intensity (FI) values. According to the results of flow cytometry, the competition binding curve was drawn with different concentrations of IgD-Fc-Ig fusion protein as the X axis and the corresponding IgD specific binding amount as the Y axis. According to the binding curve, the IC of IgD-Fc-Ig fusion p...

Embodiment 2

[0028] Embodiment 2: CCK-8 method detects IgD-Fc-Ig fusion protein to the CD4 stimulated by IgD + Effects on Cell Viability of T Cells and T-ALL Cell Lines

[0029] 2.1 Experimental method

[0030] 2.1.1 Detection of CD4 by CCK-8 method + T cell activity

[0031] 20ml of peripheral blood was extracted from healthy volunteers, treated with EDTA-K2 for anticoagulation, PBMC was separated by Ficoll density method, and CD4 was sorted by magnetic beads + T cells, and adjust the cell density to 2×10 6 / ml, add 100 μl to each well and inoculate in a 96-well culture plate. Set: blank control group (Control group), IgD group (final concentration is 3 μg / ml), IgD-Fc-Ig fusion protein single use group (0.3, 1, 3, 10, 30 μg / ml), IgD-Fc-Ig Fusion protein, IgD combined group (0.3, 1, 3, 10, 30 μg / ml+3 μg / ml IgD) and IgG-Fc recombinant protein (10 μg / ml) were placed at 37°C, 5% CO 2 Cultivate in the incubator for 24h. After terminating the culture, add 10 μl of CCK-8 reagent to each w...

Embodiment 3

[0037] Example 3: Flow cytometry detection of IgD-Fc-Ig fusion protein to IgD-stimulated CD4 + Influence of Apoptosis on T Cells and T-ALL Cell Lines

[0038] 3.1 Experimental method

[0039] CD4 + cells or Jurkat cells in 10 6 Inoculated in a 6-well plate per ml, stimulated with IgD (3 μg / ml), and added different concentrations of IgD-Fc-Ig fusion protein at the same time, at 37 ° C, 5% CO 2 After culturing in a cell culture incubator for 24 hours, collect the cells by centrifugation, wash twice with PBS, resuspend the cells in 500 μl 1×Binding Buffer, add 5 μl Annexin V-FITC and 10 μl PI to each tube, vortex gently, and incubate for 5 minutes at room temperature in the dark . On-board detection by flow cytometry.

[0040] 3.2 Experimental results

[0041] 3.2.1 The applicant has tested IgD against CD4 + The influence of T cell apoptosis and the effect of IgD-Fc-Ig, IgD (3 μg / ml) stimulation group, IgG (10 μg / ml) negative control group, IgD (3 μg / ml) + IgD-Fc-Ig fusion...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to View More

Abstract

The invention discloses application of an IgD-Fc-Ig fusion protein in preparation of drugs for treating acute lymphocytic leukemia, wherein the IgD-Fc-Ig fusion protein has an amino acid sequence as shown in SEQ ID NO.1.

Description

technical field [0001] The present invention relates to the application of IgD / IgDR as the target, and the IgD-Fc-Ig fusion protein synthesized by linking the human IgD-Fc segment and the human IgG-Fc segment to treat blood diseases, especially relates to the IgD-Fc-Ig fusion protein. Application of drugs in the treatment of acute lymphoblastic leukemia (ALL). Background technique [0002] Acute lymphoblastic leukemia (ALL) is a common malignant tumor. In recent years, with the continuous improvement of combined chemotherapy treatment, the prognosis of ALL patients has improved, but the mortality rate of children is still as high as 20%, and that of adults is as high as 50%. Acute T-lymphoblastic leukemia (T-cell acute lymphoblastic leukemia, T-ALL) is a type of ALL that is difficult to diagnose and has a high risk of recurrence, accounting for 15% of all children with ALL and 25% of all adult ALL patients . The massive proliferation of malignant T lymphoid progenitor cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P35/02
CPCA61K39/39558A61P35/02
Inventor 魏伟吴育晶陈文生
Owner 魏伟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com